Rate and predictors of carotid artery intima media thickness progression in antiretroviral-naive HIV-infected and uninfected adults: A 48-week matched prospective cohort study

Antiviral Therapy

Volumn 18, Issue 7, 2013, Pages 921-929

  Hileman, Corrilynn O ^a,b   Carman, Teresa L ^b,c   Longenecker, Chris T ^b,c   Labbato, Danielle E ^c   Storer, Norma J ^c   White, Cynthia A ^c   McComsey, Grace A ^b,c  

^a METROHEALTH MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; D DIMER; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; VIRUS RNA;

ADULT; AGE; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CAROTID ARTERY; CD4 LYMPHOCYTE COUNT; CELL ACTIVATION; COHORT ANALYSIS; COMMON CAROTID ARTERY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE MARKER; ENDOTHELIUM CELL; FAMILY HISTORY; FEMALE; GENDER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; BIOLOGICAL MARKERS; CAROTID INTIMA-MEDIA THICKNESS; FEMALE; GLUCOSE; HIV INFECTIONS; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84892736363     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2651     Document Type: Article

References (46)

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-299.
2. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005;6:99-106.
3. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008;21:93-111.
4. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and metaanalysis. Circulation 2007;115:459-467.
5. Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009;23:1841-1849.
6. McComsey GA, O'Riordan M, Hazen SL, et al. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS 2007;21:921-927.
7. Ross AC, Rizk N, O'Riordan MA, et al. Relationship between inlammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009;49:1119-1127.
8. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeiciency in HIV-associated atherosclerosis. AIDS 2009;23:1059-1067.
9. Van Vonderen MG, Smulders YM, Stehouwer CD, et al. Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. J Acquir Immune Deic Syndr 2009;50:153-161.
10. Oliviero U, Bonadies G, Apuzzi V, et al. Human immunodeiciency virus per se exerts atherogenic effects. Atherosclerosis 2009;204:586-589.
11. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004;109:1603-1608.
12. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeiciency virus disease. J Clin Endocrinol Metab 2007;92:2506-2512.
13. Lifson AR, Lando HA. Smoking and HIV: prevalence, health risks, and cessation strategies. Curr HIV/AIDS Rep 2012;9:223-230.
14. Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Deic Syndr 2008;49 Suppl 2:S79-S85.
15. Oh JY, Greene K, He H, Schafer S, Hedberg K. Population-based study of risk factors for coronary heart disease among HIV-infected persons. Open AIDS J 2012;6:177-180.
16. Mercié P, Thiebaut R, Lavignolle V, et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002;34:55-63.
17. Currier JS, Kendall MA, Zackin R, et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005;19:927-933.
18. Currier JS, Kendall MA, Henry WK, et al. Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS 2007;21:1137-1145.
19. Friis-Møller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-1735.
20. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371:1417-1426.
21. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database. J Acquir Immune Deic Syndr 2011;57:245-253.
22. Obel N, Farkas DK, Kronborg G, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med 2010;11:130-136.
23. SMART/INSIGHT Study Group, DAD Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22:F17-F24.
24. Martin A, Bloch M, Amin J, et al. Simpliication of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009;49:1591-1601.
25. Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009;23:929-939.
26. + countguided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-2296.
27. Francisci D, Giannini S, Baldelli F, et al. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS 2009;23:589-596.
28. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeiciency in HIV-associated atherosclerosis. AIDS 2009;23:1059-1067.
29. Kuller LH, Tracy R, Belloso W, et al. Inlammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5:e203.
30. Melendez MM, McNurlan MA, Mynarcik DC, Khan S, Gelato MC. Endothelial adhesion molecules are associated with inlammation in subjects with HIV disease. Clin Infect Dis 2008;46:775-780.
31. Ross AC, Armentrout R, O'Riordan MA, et al. Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Deic Syndr 2008;49:499-506.
32. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeiciency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008;52:569-576.
33. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Deic Syndr 2009;51:268-273.
34. Hileman CO, Longenecker CT, Carman TL, et al. Elevated D-dimer is independently associated with endothelial dysfunction: a cross-sectional study in HIV-infected adults on antiretroviral therapy. Antivir Ther 2012;17:1345-1349.
35. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008; pp. 1-128. (Updated 12 February 2013. Accessed 18 March 2013.) Available from http://www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf
36. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
37. Mercié P, Thiebaut R, Aurillac-Lavignolle V, et al. Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients. HIV Med 2005;6:380-387.
38. Fitch K, Looby SE, Rope A, et al. Effects of aging and smoking on carotid intima media thickness in HIV-infection. AIDS 2012;26:587-597.
39. Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease, and biomarkers of inlammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012;55:126-136.
40. Neuhaus J, Jacobs DR, Jr., Baker JV, et al. Markers of inlammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010;201:1788-1795.
41. Ross AC, O'Riordan MA, Storer N, Dogra V, McComsey GA. Heightened inlammation is linked to carotid intimamedia thickness and endothelial activation in HIV-infected children. Atherosclerosis 2010;211:492-498.
42. Hansson GK. Inlammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
43. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006;6:508-519.
44. Baker J V, Henry WK, Patel P, et al. Progression of carotid intima-media thickness in a contemporary human immunodeiciency virus cohort. Clin Infect Dis 2011;53:826-835.
45. Hsue PY, Scherzer R, Hunt PW, et al. Carotid intimamedia thickness progression in HIV-infected adults occurs preferentially at the carotid bifurcation and is predicted by inlammation. J Am Heart Assoc 2012;1:jah3-e000422.
46. Howard G, Sharrett AR, Heiss G, et al. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. Stroke 1993;24:1297-1304.